Drug Profile


Alternative Names: CanCorda; Cordaneurin

Latest Information Update: 03 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuraxo Biopharmaceuticals
  • Developer Spinal Cord Therapeutics
  • Class
  • Mechanism of Action Collagen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries

Highest Development Phases

  • Preclinical Spinal cord injuries

Most Recent Events

  • 03 Dec 2010 This programme is still in active development
  • 29 Jul 2005 Cordaneurin® will be available for licensing after clinical proof of concept (
  • 23 Sep 2004 Cordaneurin® has received Orphan Drug Status for Spinal cord injuries in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top